Klus Pharma Inc.
Clinical trials sponsored by Klus Pharma Inc., explained in plain language.
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase: PHASE1, PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for tough lung cancers
Disease control OngoingThis study tests a new drug called SKB264, given alone or with other treatments, for people with advanced or spreading non-small cell lung cancer. About 356 adults with certain genetic types of lung cancer will take part. The goal is to see if the drug is safe and shrinks tumors.
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug duo takes on multiple cancers in Mid-Stage trial
Disease control OngoingThis phase 2 study is testing a combination of two drugs, SKB264 and pembrolizumab (Keytruda), in 240 people with certain advanced solid tumors, including cervical, urothelial, ovarian, prostate, and endometrial cancers. The goal is to see if the combination is safe and effective…
Phase: PHASE2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC